Quinolinone-carboxamide compounds as 5-HT4 receptor agonists

US8309575B2 · kind B2 · utility

Assignee

• Theravance, Inc. · US

Inventors

• Daniel Marquess · Rue de l'Église, US
• Paul R. Fatheree · San Francisco, US
• S. Derek Turner · Reston, US
• Daniel D. Long · San Francisco, US
• Seok-Ki Choi · Ann Arbor, US
• Adam A. Goldblum · Berkeley, US
• Daniel Genov · Boston, US

Key dates

• Filing date: May 19, 2010
• Grant date: Nov 13, 2012
• Expiry date: Jan 22, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D451/04
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds of Formula (I). The invention also provides pharmaceutical compositions comprising such compounds, the use such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds. Wherein; R1 is hydrogen, halo, hydroxy, C1-4 alkyl, or C1-4 alkoxy; R2 is C3-4 alkyl, or C3-6cycloalkyl; R3 is hydrogen or C1-3 alkyl: R4 is S(O)2R6 or C(O)R7; R5 is hydrogen, C1-3alkyl, C2-3 alkyl substituted with —OH or C1-3 alkoxy, or —CH2-pyrydyl; R6 is C1-3 alkyl; or R5 and R6 taken together from C3-4 alkylenyl; and R7 is hydrogen, C1-3alkyl, or pyrydyl; or pharmaceutically-acceptable salt or solvate or stereoisomer thereof.